AbCellera Biologics Inc. announced a new therapeutic antibody discovery collaboration with Pfizer Inc. AbCellera will apply its proprietary monoclonal antibody (mAb) screening platform to attempt to discover function-modulating antibodies against undisclosed membrane protein targets. Under the terms of the agreement, AbCellera will receive an upfront payment and research support, and will be eligible to receive up to approximately $90 million in contingent milestone payments, as well as tiered mid-to-low single digit royalty payments based on Pfizer's development and commercialization of antibodies that may be generated under this collaboration. Further terms of the agreement are not disclosed.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
3.225 USD | +0.78% |
|
+15.60% | -42.91% |
11/07 | KeyBanc Adjusts Price Target on AbCellera Biologics to $5 From $7, Maintains Overweight Rating | MT |
13/06 | AbCellera Biologics Inc. Approves Election of Andrew Lo as Class I Director | CI |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-42.91% | 94Cr | |
+24.99% | 4.66TCr | |
+44.64% | 4.17TCr | |
-0.81% | 4.12TCr | |
+35.03% | 3.24TCr | |
+21.44% | 2.82TCr | |
-6.35% | 2.81TCr | |
+49.62% | 1.45TCr | |
+47.93% | 1.37TCr | |
+1.40% | 1.22TCr |
- Stock Market
- Equities
- ABCL Stock
- News AbCellera Biologics Inc.
- AbCellera Announces Multi-Target Research Collaboration with Pfizer